Abstract Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations occur in 25–30% of non-small cell lung cancer (NSCLC) patients. Pooled analyses in previous research have largely focused on the prognostic and predictive value of overall or common KRAS mutation status....
Abstract Lung adenocarcinoma is a prevalent and aggressive subtype of non-small cell lung cancer (NSCLC). Mutations in the Kirsten rat sarcoma viral oncogene homologue (KRAS) represent key oncogenic drivers and are associated with poor prognosis. Sotorasib is a KRAS G12C...
In this interview, Mitchell von Itzstein, MD, discusses the challenges of treating KRAS-mutant non-small cell lung cancer (NSCLC), the potential of selinexor in combination with docetaxel, and the need for further research to refine treatment strategies for this patient population....
In a groundbreaking study published in 2026, researchers have unveiled a promising therapeutic strategy for combating one of the most aggressive forms of lung cancer. The study focuses on the synergistic effects of combining cetuximab with newly developed KRAS G12C...
NEW YORK – The UK's National Institute for Health and Care Excellence (NICE) on Thursday issued a draft guidance that declined to recommend Amgen's KRAS G12C inhibitor Lumakras (sotorasib) for the treatment of previously treated KRAS G12C-mutant locally advanced or...
KRAS是人类癌症中最常见的致癌驱动基因之一，其中G12D为最主要的突变亚型，广泛...
BackgroundPatients with advanced KRAS-mutant non-small cell lung cancer (NSCLC) face a paucity of effective later-line therapies. While combining PD-1 inhibi Abstract Background: Patients with advanced KRAS-mutant non-small cell lung cancer (NSCLC) face a paucity of effective later-line therapies. While combining...
